Found: 9
Select item for more details and to access through your institution.
GNS561, a new lysosomotropic small molecule, for the treatment of intrahepatic cholangiocarcinoma.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 6, p. 1135, doi. 10.1007/s10637-019-00741-3
- By:
- Publication type:
- Article
First-In-Human Effects of PPT1 Inhibition Using the Oral Treatment with GNS561/Ezurpimtrostat in Patients with Primary and Secondary Liver Cancers.
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 3, p. 268, doi. 10.1159/000522418
- By:
- Publication type:
- Article
Prospective screening of liver fibrosis in a primary care cohort using systematic calculation of fib-4 in routine results.
- Published in:
- PLoS ONE, 2021, v. 16, n. 7, p. 1, doi. 10.1371/journal.pone.0254939
- By:
- Publication type:
- Article
GNS561 acts as a potent anti-fibrotic and pro-fibrolytic agent in liver fibrosis through TGF-β1 inhibition.
- Published in:
- Therapeutic Advances in Chronic Disease, 2020, v. 11, p. 1, doi. 10.1177/2040622320942042
- By:
- Publication type:
- Article
GNS561 acts as a potent anti-fibrotic and pro-fibrolytic agent in liver fibrosis through TGF-β1 inhibition.
- Published in:
- Therapeutic Advances in Chronic Disease, 2020, v. 11, p. 1, doi. 10.1177/2040622320942042
- By:
- Publication type:
- Article
Optimal therapy of genotype-2 chronic hepatitis C: what's new?
- Published in:
- Liver International, 2015, v. 35, p. 21, doi. 10.1111/liv.12711
- By:
- Publication type:
- Article
How to optimize current therapy of HCV genotype 1 infection with boceprevir.
- Published in:
- Liver International, 2014, v. 34, p. 4, doi. 10.1111/liv.12390
- By:
- Publication type:
- Article
GNS561 acts as a potent anti-fibrotic and pro-fibrolytic agent in liver fibrosis through TGF-β1 inhibition.
- Published in:
- Therapeutic Advances in Musculoskeletal Disease, 2020, v. 12, p. 1, doi. 10.1177/2040622320942042
- By:
- Publication type:
- Article
Ezurpimtrostat, A Palmitoyl-Protein Thioesterase-1 Inhibitor, Combined with PD-1 Inhibition Provides CD8<sup>+</sup> Lymphocyte Repopulation in Hepatocellular Carcinoma.
- Published in:
- Targeted Oncology, 2024, v. 19, n. 1, p. 95, doi. 10.1007/s11523-023-01019-8
- By:
- Publication type:
- Article